russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLCrussjcardiol-1106Research ArticleКЛИНИКА И ФАРМАКОТЕРАПИЯGUIDELINES FOR THE PRACTITIONERЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ ДВУХ РЕЖИМОВ КОМБИНИРОВАННОЙ ГИПОТЕНЗИВНОЙ ТЕРАПИИ У БОЛЬНЫХ С МЯГКОЙ И УМЕРЕННОЙ ФОРМОЙ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИEFFECTIVENESS AND SAFETY OF TWO COMBINATION ANTIHYPERTENSIVE THERAPY VARIANTS IN PATIENTS WITH MILD TO MODERATE ARTERIAL HYPERTENSIONЧеремушкинС. В.CheremushkinS. V.
к.м.н., зав. терапевтическим отделением №1 (паллиативного лечения), ассистент кафедры пропедевтики внутренних болезней и гастроэнтерологии МГМСУ, врач-терапевт высшей категории
КучерявыйЮ. А.KucheryavyiYu. A.ОганесянТ. С.OganesyanT. S.НУЗ ЦКБ №2 им. Н.А. Семашко ОАО “РЖД”, МоскваRussian Federation201128062011034045Copyright © Черемушкин С.В., Кучерявый Ю.А., Оганесян Т.С., 20112011Черемушкин С.В., Кучерявый Ю.А., Оганесян Т.С.Cheremushkin S.V., Kucheryavyi Y.A., Oganesyan T.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/1106
.
ReferencesМаколкин В.И. Позиция бета-дреноблокаторов и диуретиков в обновленных Европейских рекомендациях по артериальной гипертензии (2009)// Лечащий врач 2010; 7: 35-39.Маколкин В.И. Позиция бета-дреноблокаторов и диуретиков в обновленных Европейских рекомендациях по артериальной гипертензии (2009)// Лечащий врач 2010; 7: 35-39.Rangno R.E., Langlois S., Lutterodt A. Metoprolol withdrawal phenomena: mechanism and prevention// Clin. Pharmacol. Ther. 1982; 31: 8-15.Rangno R.E., Langlois S., Lutterodt A. Metoprolol withdrawal phenomena: mechanism and prevention// Clin. Pharmacol. Ther. 1982; 31: 8-15.Messerli F.H., Grossman E. Beta-blockers in hypertension: is carvedilol different?// Am. J.Cardiol.2004; 93(suppl):7B–12B.Messerli F.H., Grossman E. Beta-blockers in hypertension: is carvedilol different?// Am. J.Cardiol.2004; 93(suppl):7B–12B.Le Brocq M., Leslie S.J., Milliken P., et al. Endothelial dysfunction: from molecular mechanisms to measurement, clinical implications, and therapeutic opportunities // Antioxid. Redox Signal.2008;10: 1631–1674.Le Brocq M., Leslie S.J., Milliken P., et al. Endothelial dysfunction: from molecular mechanisms to measurement, clinical implications, and therapeutic opportunities // Antioxid. Redox Signal.2008;10: 1631–1674.Pedersen ME, Cockcroft JR. The vasodilatory beta-blockers// Curr. Hypertens. Rep.2007;9:269–277.Pedersen ME, Cockcroft JR. The vasodilatory beta-blockers// Curr. Hypertens. Rep.2007;9:269–277.Arosio E., De Marchi S., Prior M., et al. Effects of nebivolol and atenolol on small arteries and microcirculatory endothelium-dependent dilation in hypertensive patients undergoing isometric stress// J.Hypertens.2002;20:1793–1797.Arosio E., De Marchi S., Prior M., et al. Effects of nebivolol and atenolol on small arteries and microcirculatory endothelium-dependent dilation in hypertensive patients undergoing isometric stress// J.Hypertens.2002;20:1793–1797.Eagle K.A., Berger P.B., Calkins H., et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery-executive summary// J. Am. Coll. Cardiol. 2002; 39: 542-553.Eagle K.A., Berger P.B., Calkins H., et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery-executive summary// J. Am. Coll. Cardiol. 2002; 39: 542-553.Weiss R.J., Weber M.A., Carr A.A. et al. A randomized, doubleblind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel β-blocker, in patients with mild toтmoderate hypertension// J.Clin.Hypertens. (Greenwich)2007;9:667–676.Weiss R.J., Weber M.A., Carr A.A. et al. A randomized, doubleblind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel β-blocker, in patients with mild toтmoderate hypertension// J.Clin.Hypertens. (Greenwich)2007;9:667–676.Cleophas T.J., Agrawal R., Lichtenthal A. et al. Nationwide efficacy-safety study of nebivolol in mildly hypertensive patients// Am. J.Ther.2006;13:192–197.Cleophas T.J., Agrawal R., Lichtenthal A. et al. Nationwide efficacy-safety study of nebivolol in mildly hypertensive patients// Am. J.Ther.2006;13:192–197.Van Bortel L.M., Fici F., Mascagni F. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis// Am. J.Cardiovasc. Drugs 2008;8:35–44.Van Bortel L.M., Fici F., Mascagni F. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis// Am. J.Cardiovasc. Drugs 2008;8:35–44.Dahlof B., Lindholm L.H. et al. Morbidity and mortality in the Swedish Trial in old patients with hypertension (STOP-Hypertension)// Lancet 1991; 338, 1281–1285.Dahlof B., Lindholm L.H. et al. Morbidity and mortality in the Swedish Trial in old patients with hypertension (STOP-Hypertension)// Lancet 1991; 338, 1281–1285.Medical Research Council Working Party. MRC Trial of treatment of mild hypertension// BMJ 1985; 291: 47-104.Medical Research Council Working Party. MRC Trial of treatment of mild hypertension// BMJ 1985; 291: 47-104.The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT)// JAMA 2002; 288: 2988-2997.The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT)// JAMA 2002; 288: 2988-2997.
The authors declare that there are no conflicts of interest present.